Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

ABSTRACT: Individuals with Down syndrome (DS) are at high risk for developing Alzheimer's disease (AD) pathology and this has provided significant insights into our understanding of the genetic basis of AD. The present review summarizes recent clinical, neuropathologic, imaging, and fluid biomarker studies of AD in DS (DSAD), highlighting the striking similarities, as well as some notable differences, between DSAD and the more common late-onset form of AD (LOAD) in the general population, as well as the much rarer, autosomal-dominant form of AD (ADAD). There has been significant progress in our understanding of the natural history of AD biomarkers in DS and their relationship to clinically meaningful changes. Additional work is needed to clearly define the continuum of AD that has been described in

SUBMITTER: Rafii MS 

PROVIDER: S-EPMC7395870 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature